Hemophilia B - Epidemiology Forecast - 2036

Hemophilia B Insights and Trends

• Hemophilia B is associated with bleeding episodes, but the initial bleeding episodes in the mild and moderate are not very intense, so the patient ignores the early diagnosis, and patients are also undiagnosed in the early stages of hemophilia due to lack of diagnosis facilities.
• According to DelveInsight's estimates, the total prevalent cases of Hemophilia B in the 7MM were approximately 11,500 in 2025.
• According to the data collected by the World Federation of Hemophilia, there were approximately 25,000 cases of hemophilia in the US in 2025.
• In 2024, as per the Japan Foundation for AIDS Prevention and Ministry of Health, Labour and Welfare commissioned project, there were around 1,200 people having hemophilia B.
• According to Soucie et al. 2020, 28% of Hemophilia B patients fall into the mild category, 41% fall into moderate, and 29% into severe.
• Hemophilia A is more common than hemophilia B, representing 80-85% of the total hemophilia population

DelveInsight's 'Hemophilia B - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the Hemophilia B, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Hemophilia B Understanding and Diagnosis Algorithm

Hemophilia B Overview

Hemophilia B, also called Christmas disease, is a rare genetic bleeding disorder in which affected individual have insufficient levels of a blood protein called factor IX. Factor IX is a clotting factor and clotting factors are specialized proteins needed for blood clotting, the process by which blood Hemophilia B a wound to stop bleeding and promote healing. The severity of hemophilia that a person has is determined by the amount of factor IX (FIX) in the blood. Although there is currently no cure for Hemophilia B, treatment focuses on managing symptoms and improving quality of life. Research efforts continue to explore potential therapies and better understand the disease.

Hemophilia B Diagnosis

Diagnosis of hemophilia B is made by investigating the patient's personal history of bleeding, the patient's family history of bleeding and inheritance, and laboratory testing. Several different specialized tests are necessary to confirm a diagnosis of hemophilia B, including specialized blood coagulation tests are used to measure how long it takes the blood to clot. The initial test is the activated partial thromboplastin time (aPTT). If the results of the aPTT test are abnormal, more specific blood tests must be used to determine if the cause of the abnormal aPTT is due to a deficiency of factor IX/hemophilia B, factor VIII/hemophilia A or another clotting factor. A specific factor assay Hemophilia B determines the severity level of the factor deficiency.

Hemophilia B Epidemiology

Key Findings from Hemophilia B Epidemiological Analysis and Forecast

• According to DelveInsight's estimates, the total prevalent cases of Hemophilia B in the 7MM were approximately 11,500 in 2025.
• Among EU4 and the UK, France had highest diagnosed prevalent cases of Hemophilia B with approximately ~1,700 cases, followed by the UK and Italy. On the other hand, Spain had the lowest diagnosed prevalent cases of Hemophilia B, in 2025.
• Among the Hemophilia B patients, i.e., with or without/ Non-Inhibitors, the latter one accounts for a higher number of Hemophilia B cases. In the US, around ~250 cases accounts for inhibitor and around ~4,500 cases for non-inhibitor in 2025.
• In 2025, there were around ~1,600, ~1,700, and ~1,100 cases of mild, moderate and severe cases of hemophilia B respectively in the US.

Scope of the Report:

The report covers a segment of an executive summary, a descriptive overview of Hemophilia B, explaining its causes, signs and symptoms, and pathogenesis.

• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Hemophilia B Patient Population Forecast

Report Key Strengths

• Epidemiology-based (epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs:

• What are the disease risks, burdens, and unmet needs of Hemophilia B? What will be the growth opportunities across the 7MM concerning the patient population with Hemophilia B?
• What is the historical and forecasted Hemophilia B patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.